Bradley Hauser serves as President, Chief Executive Officer of the Company. Mr. Hauser has served as the Vice President, R&D and General Manager for CoolSculpting at Allergan Pharmaceuticals since ZELTIQ Aesthetics, Inc. was acquired by Allergan in April 2017. Previously, he served as the Senior Vice President of Research and Development at ZELTIQ Aesthetics, Inc. from January 2017 to April 2017 and as its Vice President of Research and Development from July 2015 to January 2017. Mr. Hauser joined ZELTIQ in December 2013 as Vice President of Product and Clinical Strategy. Prior to joining ZELTIQ, he held multiple roles in the aesthetic industry, including Executive Vice President of Commercial Operations for Cutera, Director of Research and Development at Medicis and Managing Director of Product and Clinical Marketing at Solta Medical. Mr. Hauser received his Bachelor of Arts in Human Biology from Stanford University.
As the President und Chief Executive Officer of Soliton, the total compensation of Bradley Hauser at Soliton is $74,514. There are 5 executives at Soliton getting paid more, with Christopher Capelli having the highest compensation of $1,111,190.
Bradley Hauser is 43, he's been the President und Chief Executive Officer of Soliton since 2020. There are 5 older and no younger executives at Soliton. The oldest executive at Soliton, Inc. is Joe Tanner, 72, who is the Chief Operating Officer.
Bradley's mailing address filed with the SEC is C/O SOLITON, INC. 5304 ASHBROOK DRIVE, , HOUSTON, TX, 77081.
Over the last 5 years, insiders at Soliton have traded over $0 worth of Soliton stock and bought 632,904 units worth $999,992 . The most active insiders traders include Walter V Klemp, Ventures Llc Remeditex und Jonathan P. Foster. On average, Soliton executives and independent directors trade stock every 126 days with the average trade being worth of $4,763,657. The most recent stock trade was executed by Ventures Llc Remeditex on 30 June 2020, trading 120,481 units of SOLY stock currently worth $999,992.
Soliton, Inc., a medical device company, develops and commercializes products using a proprietary rapid acoustic pulse technology platform. It is developing a product for the removal of tattoos. The company was founded in 2012 and is headquartered in Houston, Texas.
Soliton executives and other stock owners filed with the SEC include: